Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, with an overall 5-year survival rate of only 10-15% 1 . Deregulation of the Ras pathway is a frequent hallmark of NSCLC, often through mutations that directly activate Kras 2 . p53 is also frequently inactivated in NSCLC and, because oncogenic Ras can be a potent trigger of p53 (ref. 3), it seems likely that oncogenic Ras signalling has a major and persistent role in driving the selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic strategy for treating this disease 4 . Here we model the probable therapeutic impact of p53 restoration in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of endogenous Kras 5 . Surprisingly, p53 restoration failed to induce significant regression of established tumours, although it did result in a significant decrease in the relative proportion of high-grade tumours. This is due to selective activation of p53 only in the more aggressive tumour cells within each tumour. Such selective activation of p53 correlates with marked upregulation in Ras signal intensity and induction of the oncogenic signalling sensor p19 ARF (ref. 6). Our data indicate that p53-mediated tumour suppression is triggered only when oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early tumour evolution and in the efficacy of therapeutic p53 restoration to eradicate cancers.
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, with an overall 5-year survival rate of only 10-15% 1 . Deregulation of the Ras pathway is a frequent hallmark of NSCLC, often through mutations that directly activate Kras 2 . p53 is also frequently inactivated in NSCLC and, because oncogenic Ras can be a potent trigger of p53 (ref. 3) , it seems likely that oncogenic Ras signalling has a major and persistent role in driving the selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic strategy for treating this disease 4 . Here we model the probable therapeutic impact of p53 restoration in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of endogenous Kras 5 . Surprisingly, p53 restoration failed to induce significant regression of established tumours, although it did result in a significant decrease in the relative proportion of high-grade tumours. This is due to selective activation of p53 only in the more aggressive tumour cells within each tumour. Such selective activation of p53 correlates with marked upregulation in Ras signal intensity and induction of the oncogenic signalling sensor p19 ARF (ref. 6) . Our data indicate that p53-mediated tumour suppression is triggered only when oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early tumour evolution and in the efficacy of therapeutic p53 restoration to eradicate cancers.
Inactivation of the p53 (also known as Trp53) tumour suppressor pathway is a common feature of human cancers, fostering the attractive notion of restoring p53 function in established tumours as an effective and tumour-specific therapeutic strategy 4 . Indeed, p53 restoration was recently shown to trigger dramatic tumour regression in vivo [7] [8] [9] . Although encouraging, these studies used tumour models (either transgene 7, 9 or radiation-induced 8 ) driven by preternaturally high levels of oncogenes. Because high-level oncogene activity potently engages p53 via the p19 ARF tumour suppressor 6, 7, 10 , p53 restoration has a marked impact in these models. Unlike high oncogenic activity, however, lowlevel expression of dominant oncogenes seems insufficient to engage intrinsic tumour suppression, even though it still suffices to drive tumorigenesis 11, 12 . This raises the spectre that many epithelial malignancies, initiated as they are by low-level oncogenic signals such as those arising from mutational activation of ras genes in situ, may be insensitive to p53 restoration-at least during certain phases of their evolution. To investigate this possibility we assessed the ability of p53 restoration to trigger tumour regression in the well-characterized Lox-Stop-Lox-Kras G12D (KR) murine tumour model of NSCLC 5 wherein tumorigenesis is driven by sporadic, low-level activation of mutant Kras. This model closely recapitulates its human disease counterpart 13 .
After inhalation of adenovirus-Cre, KR mice develop multiple, independently evolving lung tumours, permitting contemporaneous analysis of different disease stages within each animal. KR mice were crossed into the p53 KI/KI switchable mouse model in which both alleles of the endogenous p53 gene are replaced by the conditional variant p53ER TAM (ref. 14) . p53 KI/KI mice can be reversibly toggled in vivo between p53 wild-type and p53 null states by administration or withdrawal of tamoxifen (Tam). Importantly, once functionally restored in Tam-treated p53 KI/KI mice, p53-mediated tumour suppression is triggered only if p53-activating signals are present 7, 10 .
Kras G12D was sporadically activated in KR;p53 KI/1 and KR;p53 KI/KI lungs and tumours were allowed to develop for 16 weeks. In both genotypes, Kras G12D activation induced a spectrum of lung tumour grades including hyperplasias, adenomas and adenocarcinomas. Like KR;p53deficient animals 15 ( Supplementary Fig. 1 ), KR;p53 KI/KI mice show accelerated tumour progression and increased incidence of high-grade tumours relative to their KR;p53 KI/1 counterparts. These data affirm that p53 restrains Kras-driven NSCLC yet indicate that, even when combined, Kras G12D activation and p53 inactivation are insufficient to generate malignant tumours without additional, aleatory mutations.
To ascertain its therapeutic impact, p53 function was restored for 1 week in KR;p53 KI/KI lung tumours ( Fig. 1a) . Surprisingly, given the marked tumour regression induced by p53 restoration in other models 7-9 , p53 restoration had no macroscopically evident impact on these tumours ( Fig. 1b ). Close inspection, however, indicated that p53 restoration did elicit a modest decrease in proliferating tumour cells ( Fig. 1c ; 14% Ki67 positive cells per Tam-treated tumours versus 21% in controls ) and an increase in apoptosis ( Supplementary Fig.  2 and Fig. 1d ; 45% of p53-restored tumours contain apoptotic cells versus 13.5% of control tumours). Nevertheless, the distribution of apoptotic cells in tumours following p53 restoration was irregular and clustered ( Fig. 1e ). This high variability in the response to sustained p53 restoration was confirmed by micro-computed tomography imaging of individual tumours over 7 days. Whereas all control tumours grew during treatment, individual Tam-treated tumours showed all possible responses-some grew, others were unchanged, and many shrank ( Fig. 2a and Supplementary Fig. 3 ). Such variability in tumour response to Tam might reflect heterogeneities among tumour cells in the efficiency of p53 restoration, in the presence of p53-activating signals, or in the engagement of downstream effectors following p53 restoration. To determine which, we first ascertained the efficiency with which Tam restored p53 function in tumours. Mice were treated for 7 days with Tam or vehicle and then exposed to a single dose of c-radiation 2 h after the last treatment to activate p53 directly. p53 activity was then monitored in individual tumours by assaying induction of the prototypical p53-responsive gene, CDKN1A (p21 cip1 ) 16, 17 . All tumours showed substantial CDKN1A induction ( Fig. 2b) , indicating that systemic Tam pervasively restores p53 function in all tumours. Hence, the heterogeneity of the therapeutic response to Tam is not a consequence of either variability in Tam-dependent p53 restoration or in the capacity of p53, once activated, to induce CDKN1A. By contrast, when p53 function was restored in the absence of concomitant DNA damage, CDKN1A was induced in only a minority of tumours ( Fig. 2b) . Hence, the variability in response to p53 restoration is because only a minority of tumours harbour endogenous p53-activating signals. Interestingly, whereas we see significant apoptosis in aggressive tumour cells following p53 restoration, other researchers do not, as described in the accompanying paper 18 , even though their mouse lung tumour model driven by spontaneous, sporadic Kras activation is ostensibly similar to ours. The reasons for this are unclear. However, the models differ in several ways. First, the mechanism of Kras activation is different, and may target distinct cell lineages with innately different sensitivities to p53-induced apoptosis. Second, they use Cre-lox recombination to restore p53 function, which is innately less synchronous than in our p53ER TAM model and may make it difficult to see a transient wave of cell death. Cre-lox recombination may also introduce additional genotoxic stresses that further modify p53 output. In the end, however, whether apoptosis or arrest is the principal output of p53 restoration in aggressive tumour cells may not be so important because both p53-induced apoptosis 7 and arrest 9 are effective at eliciting tumour clearance.
Although p53 may be activated by a wide-range of stress signals, recent in vivo studies implicate induction of p19 ARF by oncogenic signalling as the critical p53-activating trigger in established tumours 7, 10 . Because oncogenic Ras can be a potent inducer of p19 ARF (ref. 19 ), we assayed for p19 ARF expression in KR;p53 KI/KI lung tumours. Immunohistochemical analysis (IHC) of KR;p53 KI/KI lungs revealed p19 ARF expression to be highly heterogeneous-generally limited to specific regions of certain tumours. Stratification of lung tumours into low-and high-grade, the latter comprising mostly adenocarcinomas ( Supplementary Fig. 4 ) 20 , revealed that p19 ARF was confined mostly to high-grade tumours. High p19 ARF cells were only rarely 
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observed in low-grade tumours and, when present, were restricted to small, sporadic foci. Close examination of transitional tumours comprising clearly defined high-and low-grade regions showed p19 ARF to be highly expressed only in high-grade/carcinoma areas (Fig. 2c ). Because p19 ARF is a potent activator of p53, we next ascertained whether the high-grade regions expressing elevated p19 ARF coincide with those that spontaneously activate p53 following restoration. p53 function was acutely restored in KR;p53 KI/KI mice and tumours analysed for expression of p19 ARF and p21 cip1 . Upon p53 restoration, tumour areas positive for p19 ARF overlapped extensively with those positive for p21 cip1 (Fig. 2d) : ,70% of p19 ARF -positive cells from Tamtreated mice stained positive for p21 cip1 compared with 2% of control. That p19 ARF has a causal role in engaging p53-mediated tumour suppression in high-grade tumours was corroborated by the rapid cessation of cell proliferation specific to p19 ARF -positive regions following p53 restoration (Fig. 3a , Tam, two top rows). By contrast, proliferation remained high in p19 ARF -negative tumours after p53-restoration ( Fig. 3a , Tam, two bottom rows). Of note, no c-H2AX-staining DNA damage foci were detected in KR;p53 KI/KI lung tumours, although they were readily evident in tumours from c-irradiated mice ( Supplementary Fig. 5 ). This, together with the remarkable overlap between p53 activation and p19 ARF expression, strongly implicates p19 ARF , and not DNA damage, as the endogenous signal responsible for triggering p53 in high-grade lung tumours.
Although germ-line p53 deficiency significantly accelerates lung tumour progression and malignancy in KR mice 15 , our data indicate that p53 tumour suppression acts only at later stages of tumour evolution. Since p53 is specifically activated in the most atypical tumour cells, its restoration in a mixed tumour population should lead to a shift downwards in assigned tumour grade. Indeed, 7 days of p53 restoration 
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in KR;p53 KI/KI mice harbouring a mixture of low-and high-grade tumours elicited a downward shift in the frequency of high-grade tumours (from 29% to 11%) and a pro rata increase in the proportion of low-grade tumours (from 71% to 89%) ( Fig. 3b and Supplementary  Fig. 6 ). The percentage of bromodeoxyuridine (BrdU)-positive highgrade cells was also markedly reduced following treatment (Fig. 3c ). Our data show that the p19 ARF /p53 pathway is only engaged in high-grade KR;p53 KI/KI cells, even though all tumour cells harbour oncogenic Kras G12D . Hence, oncogenic activity of Kras is not alone sufficient to induce p19 ARF and engage p53-mediated tumour suppression. Interestingly, recent in vivo studies indicate that intrinsic tumour suppression is only engaged when oncogenic signals are preternaturally elevated 11, 12 . Such observations echo in vitro data showing that expression of oncogenic Kras G12D from its endogenous promoter induces proliferation and immortalization, whereas Kras G12D overexpression engages p53-dependent replicative senescence 21, 22 . Because marked upregulation of the MAPK-pathway is a characteristic feature of advanced lung tumours in both mice 15 and NSCLC in humans 23 , we asked whether induction of p19 ARF in high-grade tumours is a consequence of elevated flux through the Ras signalling network. Indeed, immunostaining showed a remarkably tight spatial concordance of tumour cells exhibiting elevated ERK phosphorylation (p-ERK), a signature of downstream Ras signalling, and those with high p19 ARF ( Fig. 4a and Supplementary Fig. 7) ; the cell-by-cell overlap between upregulation of p19 ARF and p-ERK was 91.2% (n 5 1312; s.d. 5 3.77). Hence, increased flux through oncogenic Kras G12D is the probable mechanism for both malignant progression and concomitant activation of (and eventual counter-selection against) the p19 ARF /p53 tumour suppressor pathway.
Many potential mechanisms might underlie the dramatic upregulation of p-ERK we observe in high-grade lung tumours, including changes in Kras copy number (known to occur in human NSCLC), inactivation of Kras negative feedback mechanisms and incidental activation of cooperating oncogenes [24] [25] [26] [27] . Initial analysis of whole low-versus high-grade tumours indicated downregulation of Sprouty 2 (also known as Spry2) or loss of the wild-type Kras allele as possible mechanisms for Kras signal upregulation in high p-ERK tumours ( Supplementary Fig. 8 ). Because elevated Ras signalling is a property peculiar to high-grade tumour regions, we used p-ERK staining to demarcate high, low and mixed p-ERK areas of individual tumours (Fig. 4b, upper panel) . These tumour regions were individually laser microdissected and their genomic DNA extracted and assessed for the relative copy representation of wild-type versus mutant Kras alleles. We saw variable levels of wild-type Kras retention in the low/mixed p-ERK tumour tissues, ranging from 100% in the low p-ERK tumour 14 to partial or total loss in the mixed grade tumours (for example, 21 and 18). Remarkably, the wild-type Kras allele was lost in all high p-ERK tumours (Fig. 4b, lower panel) and the mutant Kras allele often duplicated ( Supplementary Fig. 9 ). Overall, across all tumour samples Kras allelic imbalance, a known mechanism by which Ras signal strength is elevated 27 , correlated tightly with high p-ERK.
Long-lived organisms must solve the problem of suppressing cancer without compromising the facility of normal cells to proliferate. This requires an accurate means of distinguishing between normal and oncogenic signals. However, emerging evidence hints at a 'flaw' in how our tumour suppressor pathways have evolved-rather than responding to the aberrant signal persistence that is actually responsible for oncogenesis, mammalian intrinsic tumour suppressor pathways have instead evolved to respond to the unusual elevation in signal intensity that often (but not invariably) accompanies oncogenic activation 11 . Paradoxically, therefore, low-level oncogenic activities may be more efficient at initiating tumorigenesis than high-level oncogenic signals because they 'fall beneath the radar' of tumour surveillance 28 : high-level oncogenic signals, which seem necessary to drive progression to malignancy, are tolerable only once p53 function has been quelled.
At first glance, our data showing limited therapeutic impact of restoring p53 in established lung tumours seem at odds with previous studies [7] [8] [9] . However, such studies used advanced, relatively homogenous tumours driven by high levels of oncogenic signalling that had already engaged the ARF pathway-hence the dramatic impact of reinstating p53. By contrast, the spontaneously evolving lung tumours that afflict KR mice are initiated by sporadic oncogenic activation of endogenous Kras at a level insufficient to engage p53. Our data indicate that it is only relatively late in their evolution, at the point when sporadic elevation of Ras signalling precipitates tumours into aggressive, high-grade lesions, that the p53 pathway is triggered. Such considerations offer a compelling rationale for the long-baffling observation that selection for p53 pathway inactivation arises relatively late in the evolution of many solid human tumours.
The inability of low-level oncogenic signalling to engage p53 also casts a cautionary shadow over the potential efficacy of p53 restoration in treating cancer. Established tumours are typically comprised of heterogeneous clades of neoplastic clones that encompass all phases of oncogenic evolution. Although p53 restoration might cull the most malignant cells, less aggressive tumour cells driven by low-level oncogenic signals would presumably survive to evolve another day. At best, then, p53 restoration as a single therapy would be a means of temporary tumour containment rather than eradication. Immunohistochemistry and immunofluorescence. Primary antibodies used were p19 ARF (gift from C. J. Sherr and M. F. Roussel 29 ); p21 (BD Pharmingen #556430); Ki67 (SP6 Neomarkers); P-ERK (Cell Signaling Technologies #4376) and phospho-histone H2AX (Upstate #05-636). They were detected with horseradish peroxidase-/Alexa-conjugated secondary antibodies. An ApopTag kit (Millipore) was used for terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL). Laser capture microdissection, expression and copy number analysis. For CDKN1A TaqMan analysis 7 , laser capture microdissection of frozen samples 30 was followed by RNA preparation (Arcturus PicoPure RNA Isolation kit, Arcturus Engineering) and cDNA production (iScript cDNA Synthesis kit, Bio-Rad). For copy number analysis, laser microdissection (Zeiss P.A.L.M.) collection of paraffin samples was followed by DNA isolation (QIAamp DNA Micro kit #56304) and TaqMan (probes: b-actin: Mm00607939_s1; Kras: Mm03053281_s1, Applied Biosystems) or PCR (primers: KrasHind3_F 59-GCCATTAGCTGCTACAAA ACAGTA-39 and KrasHind3_R 59-CCTCTATCGTAGGGTCGTACTCAT-39). Following PCR the Kras G12D and Kras wt alleles were distinguished by the presence of a Kras G12D -specific HindIII site in the amplified fragment (wild-type 5 400 base pairs; Kras G12D 5 300 1 100 bp).
Micro-computed X-ray tomography. Pre-(day 0) and post-therapy (day 7) micro-computed tomography data was acquired using a FLEX X-O system (Gamma Medica-Ideas). Only clearly discrete tumours were measured. Immunoblot analysis. Whole-cell lysates from dissected tumour halves were immunoblotted with anti-Spry2 (Abcam ab50317), anti-Dusp6 (Santa Cruz sc-28902) or anti-b-actin (Sigma A5441) antibodies.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
